| Name | AMG-548 |
| Description | AMG-548 is a selective and orally active p38α MAPK inhibitor (Ki = 0.5 nM), with higher selectivity than p38β, p38γ, and p38δ, and can also inhibit the TNFα, CK1δ/ε, and Wnt signalling pathways. |
| In vitro | Methods: U2OS-EFC cells were treated with AMG-548 (0.01-0.1 μM) to investigate its ability to mediate Wnt-3a-induced hDvl2 mobility shift.
Results: AMG-548 inhibited hDvl2 displacement at micromolar concentrations. [2] |
| In vivo | Experimental data showed that AMG-548 exhibited differentiated pharmacokinetic characteristics in different animal models: the elimination half-life (t1/2) in rats was 4.6 hours, while in canine models it was extended to 7.3 hours. In terms of bioavailability (F value), the compound reached 62% in rats, while it was relatively low at 47% in dogs. These Results indicate that AMG-548 has significant species differences, and its metabolic clearance rate and absorption efficiency vary significantly between different animal models. [1] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 80 mg/mL (173.33 mM), Sonication is recommended.
|
| Keywords | p38δ | p38γ | p38β | p38α | p38MAPK | p38 MAPK | JNK3 | JNK2 | JNK1 | dog p38α | CK1 | AMG-548 | AMG 548 |
| Inhibitors Related | Kaolin | Urea | Acetylcysteine | Ethyl palmitate | Gum arabic | Fumaric acid | 1,8-Cineole | Dodecane | 1,4-Naphthoquinone | Tributyrin | Glucosamine | Ethyl linoleate |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Kinase Inhibitor Library | Stem Cell Differentiation Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |